$7.22
3.22% yesterday
Nasdaq, Aug 12, 10:14 pm CET
ISIN
US0887861088
Symbol
BCYC

Bicycle Therapeutics Plc Stock price

$7.22
-0.86 10.64% 1M
-5.10 41.40% 6M
-6.78 48.43% YTD
-15.83 68.68% 1Y
-19.03 72.50% 3Y
-8.50 54.07% 5Y
-6.78 48.43% 10Y
-6.78 48.43% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-0.24 3.22%
ISIN
US0887861088
Symbol
BCYC
Industry

Key metrics

Basic
Market capitalization
$529.8m
Enterprise Value
$-262.2m
Net debt
positive
Cash
$793.0m
Shares outstanding
69.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
20.6 | 14.0
EV/Sales
negative | negative
EV/FCF
1.4
P/B
0.7
Financial Health
Equity Ratio
82.9%
Return on Equity
-21.3%
ROCE
-29.5%
ROIC
-354.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$25.7m | $37.9m
EBITDA
$-236.7m | $-277.6m
EBIT
$-243.8m | $-295.6m
Net Income
$-203.2m | $-269.7m
Free Cash Flow
$-182.1m
Growth (TTM | estimate)
Revenue
-38.2% | 7.3%
EBITDA
-36.7% | -37.4%
EBIT
-35.6% | -41.3%
Net Income
-20.8% | -59.6%
Free Cash Flow
-111.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-920.2% | -733.0%
EBIT
-948.0%
Net
-790.1% | -712.2%
Free Cash Flow
-707.8%
More
EPS
$-2.9
FCF per Share
$-2.6
Short interest
6.0%
Employees
305
Rev per Employee
$120.0k
Show more

Is Bicycle Therapeutics Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Bicycle Therapeutics Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Bicycle Therapeutics Plc forecast:

15x Buy
79%
4x Hold
21%

Analyst Opinions

19 Analysts have issued a Bicycle Therapeutics Plc forecast:

Buy
79%
Hold
21%

Financial data from Bicycle Therapeutics Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
26 26
38% 38%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 76 76
22% 22%
295%
- Research and Development Expense 197 197
24% 24%
767%
-237 -237
37% 37%
-920%
- Depreciation and Amortization 7.15 7.15
8% 8%
28%
EBIT (Operating Income) EBIT -244 -244
36% 36%
-948%
Net Profit -203 -203
21% 21%
-790%

In millions USD.

Don't miss a Thing! We will send you all news about Bicycle Therapeutics Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bicycle Therapeutics Plc Stock News

Neutral
The Motley Fool
5 days ago
Bicycle (BCYC) Q2 Revenue Falls 69%
Neutral
Business Wire
5 days ago
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. “We continue to execute on our strategy, which...
Neutral
Business Wire
about one month ago
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on July 1, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 77,400 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement...
More Bicycle Therapeutics Plc News

Company Profile

Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Kevin Lee
Employees 305
Founded 2009
Website www.bicycletherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today